Great progress has been made in many countries to tackle the HIV epidemic. A newly diagnosed patient with access to the latest antiretroviral therapy (ART) can hope to have a normal life expectancy. Yet, over 30 years since the emergence of the virus, and 28 years since the first World’s AIDS Day, much more needs to done to bring these advances to developing countries and to reach groups at high risk of HIV transmission. One of the biggest barriers to achieving this aim is the stigma that is still rife in many countries.
Seeking a cure for HIVSubscription
Efforts to find a cure for HIV were reinvigorated in 2008 when the case of Timothy Ray Brown showed that a cure is possible. Researchers and pharmaceutical companies are now seeking out the virus in its hiding places in an attempt to eradicate it completely.
Pharmacist Ana Martinez explains how involving pharmacists in HIV clinical trials earned her the highest honour from the International Pharmaceutical Federation.
Unanswered questions about proposed PrEP trial Subscription
With 17 new HIV diagnoses made every day in the UK, we need to be bold and ambitious in our approach to HIV prevention — and this must include access to pre-exposure prophylaxis (PrEP) for all who need it.
On this World AIDS Day the National AIDS Trust’s theme is stigma, and there is so much that healthcare workers can do to help to combat stigma from the frontlines. The recently published UK Stigma Index highlighted the real problem in healthcare, with only 58% of people living with HIV feeling well supported by their GP practice, and 13% having heard negative comments ...
Pre-exposure prophylaxis should be a key component of a comprehensive HIV prevention package fully funded on the NHSSubscription
Pre-exposure prophylaxis (PrEP) is the medication taken by HIV-negative individuals to reduce their risk of contracting HIV infection. The large evidence base for the use of PrEP has been reviewed and recommended by the World Health Organization (WHO), a specialised agency of the United Nations that is concerned with international public health, the Joint United Nations Programme on HIV and AIDS (UNAIDS) and the National Institute for Health and Care Excellence (NICE), England’s health ...
A decision on whether to fund HIV prevention treatment on the NHS should be based on the evidence, not politics.
Researchers have raised concerns that antiretroviral drugs given to HIV patients may be increasing susceptibility to syphilis.
Combining HIV vaccination with immune stimulation delayed viral rebound in monkeys with simian immunotherapy virus.
NHS England has announced it will fund a large-scale clinical trial on the use of pre-exposure prophylaxis (PrEP) for the prevention of HIV ahead of a national roll-out.
New guideline recommends that HIV testing should be available in community settings, the voluntary sector and venues where there may be high-risk sexual behaviour.